Compare Torrent Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN TORRENT PHARMA/
LUPIN
 
P/E (TTM) x 56.6 110.2 51.4% View Chart
P/BV x 6.8 2.5 271.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   LUPIN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
LUPIN
Mar-19
TORRENT PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,550986 157.2%   
Low Rs1,144720 158.7%   
Sales per share (Unadj.) Rs354.7369.5 96.0%  
Earnings per share (Unadj.) Rs40.113.4 299.0%  
Cash flow per share (Unadj.) Rs64.237.4 171.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1303.7 89.9%  
Shares outstanding (eoy) m169.22452.49 37.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.3 164.4%   
Avg P/E ratio x33.663.6 52.8%  
P/CF ratio (eoy) x21.022.8 91.9%  
Price / Book Value ratio x4.92.8 175.5%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,897386,064 59.0%   
No. of employees `00014.717.7 83.1%   
Total wages/salary Rs m11,35331,513 36.0%   
Avg. sales/employee Rs Th4,083.09,453.8 43.2%   
Avg. wages/employee Rs Th772.31,782.0 43.3%   
Avg. net profit/employee Rs Th461.3343.0 134.5%   
INCOME DATA
Net Sales Rs m60,021167,182 35.9%  
Other income Rs m2,9883,640 82.1%   
Total revenues Rs m63,009170,822 36.9%   
Gross profit Rs m13,49328,822 46.8%  
Depreciation Rs m4,08610,850 37.7%   
Interest Rs m3,0853,078 100.2%   
Profit before tax Rs m9,31018,534 50.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m2,5299,017 28.0%   
Profit after tax Rs m6,7816,066 111.8%  
Gross profit margin %22.517.2 130.4%  
Effective tax rate %27.248.7 55.8%   
Net profit margin %11.33.6 311.4%  
BALANCE SHEET DATA
Current assets Rs m52,623138,536 38.0%   
Current liabilities Rs m52,02261,299 84.9%   
Net working cap to sales %1.046.2 2.2%  
Current ratio x1.02.3 44.8%  
Inventory Days Days12084 142.7%  
Debtors Days Days76112 67.8%  
Net fixed assets Rs m85,016127,516 66.7%   
Share capital Rs m846905 93.5%   
"Free" reserves Rs m45,376136,517 33.2%   
Net worth Rs m46,222137,422 33.6%   
Long term debt Rs m41,11566,417 61.9%   
Total assets Rs m142,432279,494 51.0%  
Interest coverage x4.07.0 57.2%   
Debt to equity ratio x0.90.5 184.0%  
Sales to assets ratio x0.40.6 70.4%   
Return on assets %6.93.3 211.7%  
Return on equity %14.74.4 332.4%  
Return on capital %14.28.9 159.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58059,414 24.5%   
Fx outflow Rs m3,60022,282 16.2%   
Net fx Rs m10,98037,132 29.6%   
CASH FLOW
From Operations Rs m8,94216,660 53.7%  
From Investments Rs m-47,070-32,825 143.4%  
From Financial Activity Rs m34,1747,441 459.2%  
Net Cashflow Rs m-3,655-8,724 41.9%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  DR. REDDYS LAB  ELDER PHARMA  UNICHEM LAB  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 6, 2019 03:31 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS